Literature DB >> 23613270

A role for RUNX1 in hematopoiesis and myeloid leukemia.

Motoshi Ichikawa1, Akihide Yoshimi, Masahiro Nakagawa, Nahoko Nishimoto, Naoko Watanabe-Okochi, Mineo Kurokawa.   

Abstract

Since its discovery from a translocation in leukemias, the runt-related transcription factor 1/acute myelogenous leukemia-1 (RUNX1/AML1), which is widely expressed in hematopoietic cells, has been extensively studied. Many lines of evidence have shown that RUNX1 plays a critical role in regulating the development and precise maintenance of mammalian hematopoiesis. Studies using knockout mice have shown the importance of RUNX1 in a wide variety of hematopoietic cells, including hematopoietic stem cells and megakaryocytes. Recently, target molecular processes of RUNX1 in normal and malignant hematopoiesis have been revealed. Although RUNX1 is not required for the maintenance of hematopoietic stem cells, it is required for the homeostasis of hematopoietic stem and progenitor cells, and expansion of hematopoietic stem and progenitor cells due to RUNX1 deletion may be an important cause of human leukemias. Molecular abnormalities cooperating with loss of RUNX1 have also been identified. These findings may lead to a further understanding of human leukemias, and suggest novel molecular targeted therapies in the near future.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23613270     DOI: 10.1007/s12185-013-1347-3

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  80 in total

1.  Down-regulation of the RUNX1-target gene NR4A3 contributes to hematopoiesis deregulation in familial platelet disorder/acute myelogenous leukemia.

Authors:  Dominique Bluteau; Laure Gilles; Morgane Hilpert; Iléana Antony-Debré; Chloe James; Najet Debili; Valerie Camara-Clayette; Orianne Wagner-Ballon; Veronique Cordette-Lagarde; Thomas Robert; Hugues Ripoche; Patrick Gonin; Sabina Swierczek; Josef Prchal; William Vainchenker; Remi Favier; Hana Raslova
Journal:  Blood       Date:  2011-07-01       Impact factor: 22.113

2.  Roles of HIPK1 and HIPK2 in AML1- and p300-dependent transcription, hematopoiesis and blood vessel formation.

Authors:  Yukiko Aikawa; Lan Anh Nguyen; Kyoichi Isono; Nobuyuki Takakura; Yusuke Tagata; M Lienhard Schmitz; Haruhiko Koseki; Issay Kitabayashi
Journal:  EMBO J       Date:  2006-08-17       Impact factor: 11.598

3.  Absence of fetal liver hematopoiesis in mice deficient in transcriptional coactivator core binding factor beta.

Authors:  K Sasaki; H Yagi; R T Bronson; K Tominaga; T Matsunashi; K Deguchi; Y Tani; T Kishimoto; T Komori
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-29       Impact factor: 11.205

4.  Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia.

Authors:  W J Song; M G Sullivan; R D Legare; S Hutchings; X Tan; D Kufrin; J Ratajczak; I C Resende; C Haworth; R Hock; M Loh; C Felix; D C Roy; L Busque; D Kurnit; C Willman; A M Gewirtz; N A Speck; J H Bushweller; F P Li; K Gardiner; M Poncz; J M Maris; D G Gilliland
Journal:  Nat Genet       Date:  1999-10       Impact factor: 38.330

5.  Analysis of the role of AML1-ETO in leukemogenesis, using an inducible transgenic mouse model.

Authors:  K L Rhoades; C J Hetherington; N Harakawa; D A Yergeau; L Zhou; L Q Liu; M T Little; D G Tenen; D E Zhang
Journal:  Blood       Date:  2000-09-15       Impact factor: 22.113

6.  PU.1 is a major downstream target of AML1 (RUNX1) in adult mouse hematopoiesis.

Authors:  Gang Huang; Pu Zhang; Hideyo Hirai; Shannon Elf; Xiaomei Yan; Zhao Chen; Steffen Koschmieder; Yutaka Okuno; Tajhal Dayaram; Joseph D Growney; Ramesh A Shivdasani; D Gary Gilliland; Nancy A Speck; Stephen D Nimer; Daniel G Tenen
Journal:  Nat Genet       Date:  2007-11-11       Impact factor: 38.330

7.  Stem cell exhaustion due to Runx1 deficiency is prevented by Evi5 activation in leukemogenesis.

Authors:  Bindya Jacob; Motomi Osato; Namiko Yamashita; Chelsia Qiuxia Wang; Ichiro Taniuchi; Dan R Littman; Norio Asou; Yoshiaki Ito
Journal:  Blood       Date:  2009-12-14       Impact factor: 22.113

8.  AML1/Runx1 negatively regulates quiescent hematopoietic stem cells in adult hematopoiesis.

Authors:  Motoshi Ichikawa; Susumu Goyama; Takashi Asai; Masahito Kawazu; Masahiro Nakagawa; Masataka Takeshita; Shigeru Chiba; Seishi Ogawa; Mineo Kurokawa
Journal:  J Immunol       Date:  2008-04-01       Impact factor: 5.422

9.  AML-1 is required for megakaryocytic maturation and lymphocytic differentiation, but not for maintenance of hematopoietic stem cells in adult hematopoiesis.

Authors:  Motoshi Ichikawa; Takashi Asai; Toshiki Saito; Sachiko Seo; Ieharu Yamazaki; Tetsuya Yamagata; Kinuko Mitani; Shigeru Chiba; Seishi Ogawa; Mineo Kurokawa; Hisamaru Hirai
Journal:  Nat Med       Date:  2004-02-15       Impact factor: 53.440

10.  AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis.

Authors:  T Okuda; J van Deursen; S W Hiebert; G Grosveld; J R Downing
Journal:  Cell       Date:  1996-01-26       Impact factor: 41.582

View more
  47 in total

Review 1.  Evolution of myeloid leukemia in children with Down syndrome.

Authors:  Satoshi Saida
Journal:  Int J Hematol       Date:  2016-02-24       Impact factor: 2.490

2.  Hematopoietic myeloid cell differentiation diminishes nucleotide excision repair.

Authors:  Yuki Aoki; Ayako Sato; Shuki Mizutani; Masatoshi Takagi
Journal:  Int J Hematol       Date:  2014-07-16       Impact factor: 2.490

3.  Differential signaling through p190 and p210 BCR-ABL fusion proteins revealed by interactome and phosphoproteome analysis.

Authors:  J A Cutler; R Tahir; S K Sreenivasamurthy; C Mitchell; S Renuse; R S Nirujogi; A H Patil; M Heydarian; X Wong; X Wu; T-C Huang; M-S Kim; K L Reddy; A Pandey
Journal:  Leukemia       Date:  2017-02-17       Impact factor: 11.528

4.  Novel function of PITH domain-containing 1 as an activator of internal ribosomal entry site to enhance RUNX1 expression and promote megakaryocyte differentiation.

Authors:  Bin Lu; Xueqin Sun; Yuxuan Chen; Qi Jin; Qin Liang; Shangqin Liu; Yamu Li; Yan Zhou; Wenxin Li; Zan Huang
Journal:  Cell Mol Life Sci       Date:  2014-08-19       Impact factor: 9.261

5.  Transcriptome-wide analysis uncovers the targets of the RNA-binding protein MSI2 and effects of MSI2's RNA-binding activity on IL-6 signaling.

Authors:  Sujitha Duggimpudi; Andreas Kloetgen; Sathish Kumar Maney; Philipp C Münch; Kebria Hezaveh; Hamed Shaykhalishahi; Wolfgang Hoyer; Alice C McHardy; Philipp A Lang; Arndt Borkhardt; Jessica I Hoell
Journal:  J Biol Chem       Date:  2018-08-20       Impact factor: 5.157

6.  Haploinsufficient tumor suppressor genes.

Authors:  Kazushi Inoue; Elizabeth A Fry
Journal:  Adv Med Biol       Date:  2017 1st Quarter

7.  RUNX1 mutations enhance self-renewal and block granulocytic differentiation in human in vitro models and primary AMLs.

Authors:  Mylène Gerritsen; Guoqiang Yi; Esther Tijchon; Jorren Kuster; Jan Jacob Schuringa; Joost H A Martens; Edo Vellenga
Journal:  Blood Adv       Date:  2019-02-12

8.  MicroRNA-378-mediated suppression of Runx1 alleviates the aggressive phenotype of triple-negative MDA-MB-231 human breast cancer cells.

Authors:  Gillian Browne; Julie A Dragon; Deli Hong; Terri L Messier; Jonathan A R Gordon; Nicholas H Farina; Joseph R Boyd; Jennifer J VanOudenhove; Andrew W Perez; Sayyed K Zaidi; Janet L Stein; Gary S Stein; Jane B Lian
Journal:  Tumour Biol       Date:  2016-01-09

9.  Internal tandem duplication of FLT3 deregulates proliferation and differentiation and confers resistance to the FLT3 inhibitor AC220 by Up-regulating RUNX1 expression in hematopoietic cells.

Authors:  Tomohiro Hirade; Mariko Abe; Chie Onishi; Takeshi Taketani; Seiji Yamaguchi; Seiji Fukuda
Journal:  Int J Hematol       Date:  2015-11-21       Impact factor: 2.490

10.  Expressional changes of genes and miRNA in common megakaryocyte-erythroid progenitors from lower-risk myelodysplastic syndrome.

Authors:  Kazuhiro Maki; Ko Sasaki; Yasunobu Nagata; Fusako Nagasawa; Yuka Nakamura; Seishi Ogawa; Kinuko Mitani
Journal:  Int J Hematol       Date:  2014-07-24       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.